Definition

A preparation of autologous T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human mesothelin (TMSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-mesothelin TCR-expressing T cells FH-TCR TMSLN specifically target and bind to mesothelin-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.